98%
921
2 minutes
20
Cell-based medicinal products (CBMPs) offer ground-breaking opportunities to treat diseases with limited or no therapeutic options. However, the intrinsic complexity of CBMPs results in great challenges with respect to analytical characterization and stability assessment. In our study, we submitted Jurkat cell suspensions to forced degradation studies mimicking conditions to which CBMPs might be exposed from procurement of cells to administration of the product. Flow imaging microscopy assisted by machine learning was applied for determination of cell viability and concentration, and quantification of debris particles. Additionally, orthogonal cell characterization techniques were used. Thawing of cells at 5 °C was detrimental to cell viability and resulted in high numbers of debris particles, in contrast to thawing at 37 °C or 20 °C which resulted in better stability. After freezing of cell suspensions at -18 °C in presence of dimethyl sulfoxide (DMSO), a DMSO concentration of 2.5% (v/v) showed low stabilizing properties, whereas 5% or 10% was protective. Horizontal shaking of cell suspensions did not affect cell viability, but led to a reduction in cell concentration. Fetal bovine serum (10% [v/v]) protected the cells during shaking. In conclusion, forced degradation studies with application of orthogonal analytical characterization methods allow for CBMP stability assessment and formulation screening.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejpb.2021.07.004 | DOI Listing |
Genes Brain Behav
October 2025
Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Major depressive disorder is a prevalent and debilitating psychiatric illness that produces significant disability. Clinical data suggest that the pathophysiology of depression is due, in part, to a dysregulation of inflammation and glutamate levels in the brain. The systemic administration of lipopolysaccharide (LPS) has been shown to induce depressive-like behaviors in mice.
View Article and Find Full Text PDFJ AOAC Int
September 2025
Analytical Development Division, Senores Pharmaceuticals, Ahmedabad, India.
Background: Molnupiravir, an FDA-approved antiviral for the treatment of COVID-19, requires reliable analytical methods to ensure its quality and safety due to its therapeutic importance.
Objectives: This study presents the development of a stability-indicating RP-HPLC method for estimating molnupiravir-related impurities in capsule formulations. An unknown impurity is structurally elucidated using LC-TQ/MS and 1H and 1³C NMR spectroscopy.
Eur J Case Rep Intern Med
August 2025
General medicine department, Universidad de Cartagena, Cartagena, Colombia.
Background: Romosozumab is a sclerostin-inhibiting monoclonal antibody that is effective and safe for anabolic treatment in patients with osteoporosis. Its main adverse effects are local; the severity of these injection-site reactions in clinical trials was generally mild.
Case Report: We present a case of a 71-year-old Colombian woman with osteoporosis at very high risk of fractures with no relevant history of drug allergies.
Metab Brain Dis
September 2025
Department of Pharmacology, SVKM's Dr Bhanuben Nanavati College of Pharmacy, V.M. Road, Vile Parle (W), Mumbai, India.
This study aimed to evaluate the antidepressant potential of Nitazoxanide (NTZ), an antiprotozoal drug with known anti-inflammatory and neuroprotective properties, in a chronic unpredictable mild stress (CUMS)-induced mice model of depression. NTZ was administered at doses of 75, 150, and 300 mg/kg, and its effects were assessed through a series of behavioral tests, including the forced swim test, tail suspension test, actophotometer test, and social interaction test. NTZ treatment at 150 and 300 mg/kg significantly improved behavioral and biochemical outcomes, relieving depressive-like symptoms and restoring neurochemical balance.
View Article and Find Full Text PDFMol Ther Nucleic Acids
September 2025
Sanofi, 1541 Avenue Marcel Mérieux, 69280 Marcy l'Etoile, France.
Messenger ribonucleic acid (mRNA), a promising tool in vaccine and therapeutic development, is reliant on intact mRNA delivery into target cells. Given its susceptibility to degradation, ensuring its stability is crucial, necessitating rigorous quality control throughout the product life cycle. This study presents an ion-pair reverse-phase liquid chromatography method that enables rapid and direct mRNA extraction from lipid nanoparticles, facilitated by using a surfactant in the sample preparation.
View Article and Find Full Text PDF